PRELUDE THERAPEUTICS INC Lease, Cost
PRELUDE THERAPEUTICS INC (PRLD) reported Lease, Cost of $4.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-10
- PRELUDE THERAPEUTICS INC lease, cost for the quarter ending 2024-03-31 was $1.10M, a 120.00% increase year-over-year.
- PRELUDE THERAPEUTICS INC lease, cost for the quarter ending 2023-03-31 was $500.00K.
- PRELUDE THERAPEUTICS INC lease, cost for fiscal 2025 was $4.40M, a 0.00% change from fiscal 2024.
- PRELUDE THERAPEUTICS INC lease, cost for fiscal 2024 was $4.40M, a 76.00% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC lease, cost for fiscal 2023 was $2.50M, a 19.05% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC lease, cost for fiscal 2022 was $2.10M.
| Period end | Lease, Cost 3 month | Lease, Cost 12 month |
|---|---|---|
| 2025-12-31 | $4.40M 10-K · filed 2026-03-10 | |
| 2024-12-31 | $4.40M 10-K · filed 2025-03-10 | |
| 2024-03-31 | $1.10M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $2.50M 10-K · filed 2025-03-10 | |
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $2.10M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |